Literature DB >> 1440877

Development of GPIIb/IIIa antagonists as antithrombotic drugs.

A J Nichols1, R R Ruffolo, W F Huffman, G Poste, J Samanen.   

Abstract

Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombosis, namely platelet aggregation, and how it can be inhibited by antagonists of the adhesion molecule GPIIb/IIIa. Successful and future therapeutic applications of GPIIb/IIIa antagonists, and their pharmacology, are considered in detail.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1440877     DOI： 10.1016/0165-6147(92)90126-q

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  7 in total

1.  Intestinal absorption barriers and transport mechanisms, including secretory transport, for a cyclic peptide, fibrinogen antagonist.

Authors:  B J Aungst; H Saitoh
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

Review 2.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

Review 3.  Antiplatelet drugs. A comparative review.

Authors:  K Schrör
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

4.  Determination of the structure of two novel echistatin variants and comparison of the ability of echistatin variants to inhibit aggregation of platelets from different species.

Authors:  Y L Chen; T F Huang; S W Chen; I H Tsai
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

5.  Molecular cloning and expression of catrocollastatin, a snake-venom protein from Crotalus atrox (western diamondback rattlesnake) which inhibits platelet adhesion to collagen.

Authors:  Q Zhou; J B Smith; M H Grossman
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

6.  Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.

Authors:  G Müller; M Gurrath; H Kessler
Journal:  J Comput Aided Mol Des       Date:  1994-12       Impact factor: 3.686

7.  Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa.

Authors:  T Satoh; W C Kouns; Y Yamashita; T Kamiyama; B Steiner
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.